XML 31 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
LONG-TERM DEBT LONG-TERM DEBT (Tables)
 3 Months Ended
Nov. 02, 2019
Debt Disclosure [Abstract]  
Schedule of Debt
The Company’s long-term debt consisted of the following:
(in thousands)
Average Interest Rate at
November 2, 2019
 
Calendar Maturity Year
 
November 2,
2019
 
August 3,
2019
Term Loan Facility
6.04%
 
2025
 
$
1,786,500

 
$
1,864,900

ABL Credit Facility
3.14%
 
2023
 
1,317,700

 
1,080,000

Other secured loans
5.20%
 
2023-2024
 
58,417

 
57,649

Debt issuance costs, net
 
 
 
 
(52,374
)
 
(54,891
)
Original issue discount on debt
 
 
 
 
(39,787
)
 
(41,175
)
Long-term debt, including current portion
 
 
 
 
3,070,456

 
2,906,483

Less: current portion of long-term debt
 
 
 
 
(19,218
)
 
(87,433
)
Long-term debt
 
 
 
 
$
3,051,238

 
$
2,819,050
Schedule of Line of Credit Facilities
The assets included in the Condensed Consolidated Balance Sheets securing the outstanding obligations under the ABL Credit Facility on a first-priority basis, and the unused available credit and fees under the ABL Credit Facility, were as follows:
Assets securing the ABL Credit Facility (in thousands)(1):
November 2, 2019
Certain inventory assets included in Inventories and Current assets of discontinued operations
$
2,447,555

Certain receivables included in Accounts receivables, net and Current assets of discontinued operations
$
1,077,978

(1)
The ABL Credit Facility is also secured by all of the Company’s pharmacy scripts, which are included in Long-term assets of discontinued operations in the Condensed Consolidated Balance Sheets as of November 2, 2019.

Unused available credit and fees under the ABL Credit Facility (in thousands, except percentages):
November 2, 2019
Outstanding letters of credit
$
77,413

Letter of credit fees
1.375
%
Unused available credit
$
695,704

Unused facility fees
0.25
%